4506 — Sumitomo Pharma Share News
0.000.00%
Last trade - 00:00- ¥826bn
- ¥902bn
- ¥453bn
Regarding A Report Concerning Sumitomo Pharma ( Company's Views On Gcr August 7 Report)
Brief: Sumitomo Pharma - Gotham City Research's August 3 Report Contains Numerous Statements That Are Clearly Inconsistent With Facts
Brief: Gotham City Research Holds Short Positions In Sumitomo Chemical And Sumitomo Pharmaceutical
Table: Sumitomo Pharma -Q1 group results (IFRS)
Brief: Sumitomo Pharma America Announces Enzomenib (Dsp-5336) Receives FDA Orphan Drug Designation For Treatment Of Acute Lymphoblastic Leukemia
Smbc Nikko Securities Notified It Will Not Subscribe For Any Shares, Accordingly Issuance Of New Shares By Way Of Third: Party Allotment Will Not Be Implemented
Table: Sumitomo Pharma -2025/26 parent results
Table: Sumitomo Pharma -2025/26 group results (IFRS)
Notice Regarding Withdrawal Of Shelf Registration Statement For Issuance Of New Shares
Notice Regarding Determination Of Issue Price, Selling Price And Other Matters
Will Conduct New Share Offering
To Refinance Existing Borrowings Through A Bridge Loan
Will Conduct Secondary Share Offering
Japanese stocks surrender gains over Middle East war concerns
Brief: Sumitomo Pharma America Announces That Its Investigational Therapy Dsp-3077 Has Received FDA Orphan Drug Designation For The Treatment Of Retinitis Pigmentosa
Announcement On Approval For Maa Of Allogeneic Ips Cell-Derived Dopaminergic Neural Progenitor Cell Product "Amchepry" In Japan
Announcement Of Filing Of Shelf Registration Statement For Issuance Of New Shares
Table: Sumitomo Pharma -2025/26 group forecast(IFRS)
Japanese government panel endorses Sumitomo Pharma's iPS-derived treatment for Parkinson's (updated)